EP1025090A4 - Vitronectin receptor antagonists - Google Patents
Vitronectin receptor antagonistsInfo
- Publication number
- EP1025090A4 EP1025090A4 EP98947116A EP98947116A EP1025090A4 EP 1025090 A4 EP1025090 A4 EP 1025090A4 EP 98947116 A EP98947116 A EP 98947116A EP 98947116 A EP98947116 A EP 98947116A EP 1025090 A4 EP1025090 A4 EP 1025090A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- receptor antagonists
- vitronectin receptor
- vitronectin
- antagonists
- receptor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/48—Nitrogen atoms not forming part of a nitro radical with acyclic hydrocarbon or substituted acyclic hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
- C07D239/12—Nitrogen atoms not forming part of a nitro radical
- C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/02—Seven-membered rings
- C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
- C07D313/10—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with two six-membered rings
- C07D313/14—[b,f]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5934297P | 1997-09-19 | 1997-09-19 | |
US59342P | 1997-09-19 | ||
US6343897P | 1997-10-29 | 1997-10-29 | |
US63438P | 1997-10-29 | ||
PCT/US1998/019466 WO1999015508A1 (en) | 1997-09-19 | 1998-09-18 | Vitronectin receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1025090A1 EP1025090A1 (en) | 2000-08-09 |
EP1025090A4 true EP1025090A4 (en) | 2000-11-08 |
Family
ID=26738652
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP98947116A Withdrawn EP1025090A4 (en) | 1997-09-19 | 1998-09-18 | Vitronectin receptor antagonists |
Country Status (26)
Country | Link |
---|---|
EP (1) | EP1025090A4 (en) |
JP (1) | JP2001517658A (en) |
KR (1) | KR20010024141A (en) |
CN (1) | CN1278250A (en) |
AP (1) | AP2000001766A0 (en) |
AR (1) | AR015446A1 (en) |
AU (1) | AU738433B2 (en) |
BG (1) | BG104314A (en) |
BR (1) | BR9812340A (en) |
CA (1) | CA2303487A1 (en) |
CO (1) | CO5011087A1 (en) |
DZ (1) | DZ2609A1 (en) |
EA (1) | EA200000336A1 (en) |
HU (1) | HUP0003641A3 (en) |
ID (1) | ID24162A (en) |
IL (1) | IL135028A0 (en) |
MA (1) | MA26547A1 (en) |
NO (1) | NO20001407L (en) |
NZ (1) | NZ503389A (en) |
OA (1) | OA11341A (en) |
PE (1) | PE122699A1 (en) |
PL (1) | PL339381A1 (en) |
SK (1) | SK4082000A3 (en) |
TR (1) | TR200000721T2 (en) |
TW (1) | TW513303B (en) |
WO (1) | WO1999015508A1 (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CO4920232A1 (en) * | 1997-01-08 | 2000-05-29 | Smithkline Beecham Corp | DIBENZO [A, D] CYCLLOHEPTANE ACETIC ACIDS WITH VITRONECTIN RECEPTOR ANTAGONIST ACTIVITY |
EP1150965A4 (en) | 1999-02-03 | 2002-05-15 | Merck & Co Inc | Benzazepine derivatives as alpha-v integrin receptor antagonists |
DE19936780A1 (en) * | 1999-08-09 | 2001-02-15 | Basf Ag | New integrin receptor antagonists |
US6881736B1 (en) | 1999-09-07 | 2005-04-19 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
EG24179A (en) * | 1999-09-07 | 2008-09-28 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
FR2806082B1 (en) * | 2000-03-07 | 2002-05-17 | Adir | NOVEL BICYCLIC ANTAGONIST VITRONECTIN RECEPTOR COMPOUNDS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
EP1289959A1 (en) | 2000-06-15 | 2003-03-12 | Pharmacia Corporation | Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists |
ATE320258T1 (en) * | 2000-10-24 | 2006-04-15 | Merck & Co Inc | DIBENZOXAZEPINE ALPHA V INTEGRIN RECEPTOR ANTAGONIST |
EP1381384B1 (en) | 2001-04-24 | 2011-05-25 | Merck Patent GmbH | COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNFalpha |
GB0215867D0 (en) * | 2002-07-09 | 2002-08-14 | Glaxosmithkline Spa | Novel method and compounds |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
EP2335733B1 (en) | 2006-01-18 | 2014-08-06 | Merck Patent GmbH | Specific therapy using integrin ligands for treating cancer |
CN101588812A (en) | 2007-01-18 | 2009-11-25 | 默克专利有限公司 | Specific therapy and medicament using integrin ligands for treating cancer |
WO2010136168A2 (en) | 2009-05-25 | 2010-12-02 | Merck Patent Gmbh | Continuous administration of integrin ligands for treating cancer |
EP3148587B1 (en) | 2014-05-30 | 2021-02-24 | Pfizer Inc | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997001540A1 (en) * | 1995-06-29 | 1997-01-16 | Smithkline Beecham Corporation | Integrin receptor antagonists |
WO1998015278A1 (en) * | 1996-10-07 | 1998-04-16 | Smithkline Beecham Corporation | Method for stimulating bone formation |
WO1998030542A1 (en) * | 1997-01-08 | 1998-07-16 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH450398A (en) * | 1964-02-18 | 1968-01-31 | Hoffmann La Roche | Process for the preparation of dibenzocycloheptatriene compounds |
US3335148A (en) * | 1966-02-17 | 1967-08-08 | Lilly Co Eli | 9(3-pyridyl)derivative of fluorene, 9-fluorenol, xanthene, 9-xanthenol and the corresponding nonphytotoxic acid addition salts thereof |
US5698551A (en) * | 1995-04-07 | 1997-12-16 | Novo Nordisk A/S | Heterocyclic compounds |
US5659033A (en) * | 1995-09-13 | 1997-08-19 | Neurogen Corporation | N-aminoalkylfluorenecarboxamides; a new class of dopamine receptor subtype specific ligands |
-
1998
- 1998-09-16 AR ARP980104604A patent/AR015446A1/en not_active Application Discontinuation
- 1998-09-16 DZ DZ980219A patent/DZ2609A1/en active
- 1998-09-16 PE PE1998000881A patent/PE122699A1/en not_active Application Discontinuation
- 1998-09-18 IL IL13502898A patent/IL135028A0/en unknown
- 1998-09-18 CA CA002303487A patent/CA2303487A1/en not_active Abandoned
- 1998-09-18 SK SK408-2000A patent/SK4082000A3/en unknown
- 1998-09-18 CN CN98810811A patent/CN1278250A/en active Pending
- 1998-09-18 WO PCT/US1998/019466 patent/WO1999015508A1/en not_active Application Discontinuation
- 1998-09-18 JP JP2000512816A patent/JP2001517658A/en not_active Withdrawn
- 1998-09-18 TR TR2000/00721T patent/TR200000721T2/en unknown
- 1998-09-18 AU AU93972/98A patent/AU738433B2/en not_active Ceased
- 1998-09-18 ID IDW20000468A patent/ID24162A/en unknown
- 1998-09-18 NZ NZ503389A patent/NZ503389A/en not_active IP Right Cessation
- 1998-09-18 BR BR9812340-8A patent/BR9812340A/en not_active Application Discontinuation
- 1998-09-18 HU HU0003641A patent/HUP0003641A3/en unknown
- 1998-09-18 PL PL98339381A patent/PL339381A1/en unknown
- 1998-09-18 EA EA200000336A patent/EA200000336A1/en unknown
- 1998-09-18 EP EP98947116A patent/EP1025090A4/en not_active Withdrawn
- 1998-09-18 AP APAP/P/2000/001766A patent/AP2000001766A0/en unknown
- 1998-09-18 MA MA25266A patent/MA26547A1/en unknown
- 1998-09-18 KR KR1020007002901A patent/KR20010024141A/en not_active Application Discontinuation
- 1998-09-18 CO CO98053986A patent/CO5011087A1/en unknown
- 1998-09-23 TW TW087115535A patent/TW513303B/en not_active IP Right Cessation
-
2000
- 2000-03-16 OA OA1200000079A patent/OA11341A/en unknown
- 2000-03-17 NO NO20001407A patent/NO20001407L/en not_active Application Discontinuation
- 2000-04-07 BG BG104314A patent/BG104314A/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997001540A1 (en) * | 1995-06-29 | 1997-01-16 | Smithkline Beecham Corporation | Integrin receptor antagonists |
WO1998015278A1 (en) * | 1996-10-07 | 1998-04-16 | Smithkline Beecham Corporation | Method for stimulating bone formation |
WO1998030542A1 (en) * | 1997-01-08 | 1998-07-16 | Smithkline Beecham Corporation | Vitronectin receptor antagonists |
Non-Patent Citations (1)
Title |
---|
See also references of WO9915508A1 * |
Also Published As
Publication number | Publication date |
---|---|
AP2000001766A0 (en) | 1998-09-18 |
HUP0003641A2 (en) | 2001-03-28 |
BG104314A (en) | 2001-01-31 |
KR20010024141A (en) | 2001-03-26 |
IL135028A0 (en) | 2001-05-20 |
PL339381A1 (en) | 2000-12-18 |
NO20001407D0 (en) | 2000-03-17 |
SK4082000A3 (en) | 2000-09-12 |
HUP0003641A3 (en) | 2002-10-28 |
JP2001517658A (en) | 2001-10-09 |
NO20001407L (en) | 2000-03-17 |
CA2303487A1 (en) | 1999-04-01 |
AU9397298A (en) | 1999-04-12 |
AR015446A1 (en) | 2001-05-02 |
NZ503389A (en) | 2002-03-28 |
TW513303B (en) | 2002-12-11 |
ID24162A (en) | 2000-07-13 |
CO5011087A1 (en) | 2001-02-28 |
DZ2609A1 (en) | 2003-03-01 |
WO1999015508A1 (en) | 1999-04-01 |
EP1025090A1 (en) | 2000-08-09 |
PE122699A1 (en) | 2000-02-12 |
AU738433B2 (en) | 2001-09-20 |
EA200000336A1 (en) | 2000-10-30 |
MA26547A1 (en) | 2004-12-20 |
BR9812340A (en) | 2001-12-18 |
OA11341A (en) | 2003-12-10 |
TR200000721T2 (en) | 2000-11-21 |
CN1278250A (en) | 2000-12-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY2576B1 (en) | Vitronectin receptor antagonists | |
IL130760A0 (en) | Vitronectin receptor antagonists | |
EP0767792A4 (en) | Vitronectin receptor antagonists | |
ZA955391B (en) | Vitronectin receptor antagonists | |
EP1000031A4 (en) | Vitronectin receptor antagonist | |
IL125030A0 (en) | Vitronectin receptor antagonists | |
EP1047425A4 (en) | Integrin receptor antagonists | |
HUP9900754A3 (en) | Vitronectin receptor antagonists | |
IL125034A0 (en) | Vitronectin receptor antagonists | |
EP1007051A4 (en) | Integrin receptor antagonists | |
IL135028A0 (en) | Vitronectin receptor antagonists | |
IL135189A0 (en) | Vitronectin receptor antagonist | |
IL138245A0 (en) | Vitronectin receptor antagonists | |
IL135188A0 (en) | Vitronectin receptor antagonist | |
EP1027337A4 (en) | Integrin receptor antagonists | |
IL141163A0 (en) | Vitronectin receptor antagonists | |
ZA988562B (en) | Vitronectin receptor antagonists | |
SI0957917T1 (en) | Vitronectin receptor antagonists | |
GB9811295D0 (en) | Vitronectin receptor antagonists | |
GB9815803D0 (en) | Vitronectin receptor antagonists | |
GB9822331D0 (en) | Vitronectin receptor antagonists | |
GB9812686D0 (en) | Vitronectin receptor antagonists | |
GB9807382D0 (en) | Vitronectin receptor antagonists | |
GB9810882D0 (en) | Vitronectin receptor antagonists | |
GB9810892D0 (en) | Vitronectin receptor antagonists |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000327 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: RO PAYMENT 20000327;SI PAYMENT 20000327 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20000926 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 213/74 A, 7A 61K 31/44 B, 7C 07D 213/73 B, 7C 07D 217/22 B, 7C 07D 239/14 B, 7C 07D 277/42 B, 7C 07D 405/12 B |
|
17Q | First examination report despatched |
Effective date: 20030207 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20030819 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1031115 Country of ref document: HK |